Ardelyx Releases First ESG Report
Ardelyx, a biopharmaceutical firm with a goal of discovering, developing, and marketing pioneering, first-of-their-kind drugs to fulfill major unmet medical needs, has issued its inaugural Environmental, Social, and Governance (ESG) Report for 2022, highlighting its sustainability efforts in these fields for the first time.
“I am pleased to share our 2022 Ardelyx ESG report, which showcases the ways we have invested in our patients, employees, and the communities we serve to build a more equitable and sustainable society,” said Mike Raab, president and chief executive officer of Ardelyx. “In recent years, we have proven our resilience as a company, as a society and as individuals, and all of us at Ardelyx are committed to continuing to adapt and grow. While we are still early in our ESG journey, I am proud of the foundation and culture within Ardelyx that embraces social consciousness and sustainability. We look forward to continuing to work with our stakeholders, with a priority towards the patients we seek to serve, to shape a better future for all.”
Highlights of the ESG report include the following:
Ardelyx launched ArdelyxAssist™, a patient services programme that offers access and affordability support to patients and healthcare providers.
The company donated more than $2 million to support educational healthcare programmes for healthcare providers, patients, and caregivers.
Over 11 pallets of R&D supplies and equipment were contributed to non-profit STEM organisations.
Ardelyx sponsored the California Life Sciences Association Racial and Social Equity Initiative, which aims to promote racial and social equity in the life sciences industry in California.
Ardelyx was recognised as one of the "Deloitte Technology Fast 500™," which ranks the fastest-growing companies in North America across various industries, including technology, media, telecommunications, life sciences, fintech, and energy tech.
Ardelyx's ESG report covers its ESG initiatives, which include patient access and affordability, product quality management, safety, and clinical study standards, patient advocacy and corporate giving, training and development, diversity, equity, and inclusion, employee health, safety, and wellness, COVID-19 response, governance and leadership, business ethics and compliance, ethical marketing, and data privacy. The report can be viewed in its entirety here.
For more investor-related news